Infective complications after transcatheter aortic valve implantation: results from a single centre.

Division of Cardiology, University Medical Centre Utrecht, UMC Utrecht, Heidelberglaan 100, Utrecht, Postbus 85500, 3508 GA, Utrecht, the Netherlands, .
Netherlands heart journal: monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation (Impact Factor: 2.26). 08/2012; 20(9):360-4. DOI: 10.1007/s12471-012-0303-9
Source: PubMed

ABSTRACT After its first introduction in 2002, transcatheter aortic valve implantation (TAVI) has continuously gained more foothold for the treatment of severe aortic stenosis and is nowadays a viable treatment option for inoperable patients or patients at high risk for conventional surgical aortic valve replacement. Although ideally carried out in a so-called hybrid room, incorporating both the strict hygiene and advanced life support possibilities of the operating theatre and the imaging and percutaneous arsenal of the catheterisation suite, in most centres TAVI is at present performed in the catheterisation laboratory. This may raise concern about an increased risk of infection, since there the criteria that are applied regarding disinfection and sterilisation are not as stringent as those of the operating theatre. Therefore, we retrospectively assessed the number of infective complications in patients undergoing TAVI in the catheterisation lab of our institution. Eleven out of 73 patients developed a postprocedural infection, one of which could be attributed to the procedure itself, being superinfection of a surgical groin cut-down. Our conclusion is that percutaneous aortic valve implantation in a catheterisation laboratory is not associated with an increased risk of infective complications.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Fever following transcatheter aortic valve implantation (TAVI) is common and may result in extensive workup, treatment with broad spectrum antibiotics and prolonged hospitalization. Despite these consequences, the prevalence and nature of fever after TAVI, and whether cases of fever could be attributed to an infectious origin have not been studied thoroughly to date. We conducted an observational retrospective analysis of 148 consecutive patients undergoing percutaneous transfemoral TAVI at the Tel-Aviv Medical Center. All patients were treated with antibiotic prophylaxis using first or second generation cephalosporins (or vancomycin upon a beta-lactam allergy) on procedure day. Medical and nursing records were reviewed for the occurrence, extent and origin of fever. Laboratory databases were screened for positive cultures. Fever above 37.5°C occurred in 66 (47%) patients and ≥38.0°C in 27 (19.4%) patients. Most febrile episodes ≥38.0°C were of short duration, lasting less than 8 hours (59.3%, n=16) and occurred in the first 48 hours following procedure (74%, n=22). Bacteremia was found in 2 cases and urinary tract infection in 3 other cases; most pathogens isolated were resistant to prophylactic antibiotic regimen. Unlike prolonged fever, a short febrile episode was not associated with an extended hospital stay or with increased 30 days mortality following TAVI. In conclusion, fever following TAVI occurs frequently, and may represent a non-infectious inflammatory response as it rarely associates with a documented bacterial infection. Therefore, deferring antibiotic therapy in an otherwise well post-TAVI patient with a short febrile episode should be considered, while prolonged and high-grade fever warrants further workup and empiric antibiotic therapy.
    The American journal of cardiology 01/2013; · 3.58 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Transcatheter aortic valve replacement (TAVR) is a new therapy for severe aortic stenosis now available in the United States. Initial patients eligible for TAVR are defined by high operative risk, with advanced age and multiple comorbidities. Following TAVR, patients experience acute hemodynamic changes and several possible complications, including hypotension, vascular injury, anemia, stroke, new-onset atrial fibrillation, conduction disturbances and kidney injury, requiring an acute phase of intensive care. Alongside improvements in TAVR technology and technique, improvements in care after TAVR may contribute to improved outcomes. This review presents an approach to post-TAVR critical care and identifies directions for future research.
    Cardiology clinics 11/2013; 31(4):607-18. · 1.25 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Transcatheter aortic valve implantation (TAVI) has been proposed to treat older surgical high-risk patients with severe symptomatic aortic stenosis. There are no data regarding short-term and long-term infectious complications in these patients. The objective of this study was to define the incidence, etiology and outcome of early and late infectious complications following TAVI compared to patients >65 years-old undergoing traditional surgical aortic replacement (SAR). This was a prospective observational study evaluating all consecutive patients who underwent TAVI or SAR. Follow-up was performed up to 1 year after the procedure of valve implantation. Fifty-one patients underwent TAVI and were compared to 102 patients who underwent SAR. Compared to SAR patients, those who underwent TAVI had lower incidence of early post-operative (11.7% vs 26.4%, p=0.04), intermediate (5.9% vs 17.6%, p=0.01) and late infections (7.8% vs 11.7%, p=0.03). Among SAR patients the most common infections were bloodstream infections, pneumonias, urinary tract infections, and sternal wound infections. Patients who underwent TAVI had a longer survival without infection (358 days vs 312.9, p=0.006). There were no significant differences in 12-month crude survival between the two study populations. Despite a high frequency of coexisting illnesses, patients undergoing TAVI develop few infectious complications. TAVI appears to be a reasonable and safe option in high-risk patients with severe symptomatic aortic stenosis. This article is protected by copyright. All rights reserved.
    Clinical Microbiology and Infection 11/2013; · 4.58 Impact Factor

Full-text (2 Sources)

Available from
May 17, 2014